scholarly journals Evaluation of the Final Adult Height and Its Determinants in Patients with Growth Hormone Deficiency: A Single-centre Experience from the South-Eastern Region of Turkey

2020 ◽  
Vol 12 (3) ◽  
pp. 295-302
Author(s):  
Meliha Demiral ◽  
Edip Unal ◽  
Birsen Baysal ◽  
Rıza Taner Baran ◽  
Hüseyin Demirbilek ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Adult Height ◽  
Hormone Deficiency ◽  
Eastern Region ◽  
The South ◽  
Single Centre ◽  
South Eastern ◽  
Final Adult Height ◽  
Single Centre Experience

Comparison of the Effectiveness of Adult Height Prediction Methods in Children with Growth Hormone Deficiency

2021 ◽  
pp. 1-8
Author(s):  
İbrahim Mert Erbaş ◽  
Zeynep Ölmez ◽  
Ahu Paketçi ◽  
Korcan Demir ◽  
Ece Böber ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Adult Height ◽  
Hormone Deficiency ◽  
Prediction Methods ◽  
Height Prediction

scholarly journals Prediction of Adult Height in Growth-Hormone-Treated Children with Growth Hormone Deficiency

2007 ◽  
Vol 92 (3) ◽  
pp. 925-931 ◽  
Author(s):  
Maria A. J. de Ridder ◽  
Theo Stijnen ◽  
Anita C. S. Hokken-Koelega
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Adult Height ◽  
Hormone Deficiency

scholarly journals Validation of Prediction Models for Near Adult Height in Children with Idiopathic Growth Hormone Deficiency Treated with Growth Hormone: A Belgian Registry Study

2016 ◽  
Vol 86 (3) ◽  
pp. 161-168 ◽  
Author(s):  
Saartje Straetemans ◽  
Jean De Schepper ◽  
Muriel Thomas ◽  
Franciska Verlinde ◽  
Raoul Rooman ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Adult Height ◽  
Prediction Models ◽  
Hormone Deficiency ◽  
Registry Study ◽  
Idiopathic Growth Hormone Deficiency

scholarly journals Effectiveness and Overall Safety of NutropinAq® for Growth Hormone Deficiency and Other Paediatric Growth Hormone Disorders: Completion of the International Cooperative Growth Study, NutropinAq® European Registry (iNCGS)

2021 ◽  
Vol 12 ◽  
Author(s):  
Regis Coutant ◽  
Jordi Bosch Muñoz ◽  
Cristina Patricia Dumitrescu ◽  
Dirk Schnabel ◽  
Caroline Sert ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Adult Height ◽  
Recombinant Human Growth Hormone ◽  
Standard Deviation Score ◽  
Hormone Deficiency ◽  
Growth Disorders ◽  
Growth Study ◽  
Post Marketing Surveillance ◽  
European Registry

ObjectiveThe International Cooperative Growth Study, NutropinAq® European Registry (iNCGS) (NCT00455728) monitored long-term safety and effectiveness of recombinant human growth hormone (rhGH; NutropinAq® [somatropin]) in paediatric growth disorders.MethodsOpen-label, non-interventional, post-marketing surveillance study recruiting children with growth disorders. Endpoints included gain in height standard deviation score (SDS), adult height, and occurrence of adverse events (AEs).Results2792 patients were enrolled. 2082 patients (74.6%) had growth hormone deficiency (GHD), which was isolated idiopathic in 1825 patients (87.7%). Non-GHD diagnoses included Turner syndrome (TS) (n=199), chronic renal insufficiency (CRI) (n=10), other non-GHD (n=498), and missing data for three participants. Improvements from baseline height SDS occurred at all time points to Month 132, and in all subgroups by disease aetiology. At Month 12, mean (95% CI) change in height SDS by aetiology was: idiopathic GHD 0.63 (0.61;0.66), organic GHD 0.71 (0.62;0.80), TS 0.59 (0.53; 0.65), CRI 0.54 (-0.49;1.56), and other non-GHD 0.64 (0.59;0.69). Mean height ( ± SD) at the last visit among the 235 patients with adult or near-adult height recorded was 154.0 cm ( ± 8.0) for girls and 166.7 cm ( ± 8.0) for boys. The most frequent biological and clinical non-serious drug-related AEs were increased insulin-like growth factor concentrations (314 events) and injection site haematoma (99 events). Serious AEs related to rhGH according to investigators were reported (n=30); the most frequent were scoliosis (4 events), epiphysiolysis (3 events), and strabismus (2 events).ConclusionsThere was an improvement in mean height SDS in all aetiology subgroups after rhGH treatment. No new safety concerns were identified.

Sign in / Sign up

Export Citation Format

Share Document